Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Developmental Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HOXC13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HOXC13 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biochemical interaction assays. |
View HOXC13 Products |
| Gene Delivery | HOXC13 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic validation. |
View HOXC13 Products |
| Benchmark Ab | Anti-HOXC13 Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and IHC validation. |
View HOXC13 Products |
| Validator | HOXC13 siRNA Set For target knockdown verification and specificity profiling. |
View HOXC13 Products |
| Related Target A | AR (Androgen Receptor) Synergistic driver; HOXC13 acts as a co-factor modulating AR signaling in prostate cancer. |
View AR Products |
| Related Target B | FOXA1 Pioneering transcription factor; co-localizes with HOXC13 to drive lineage-specific oncogenesis. |
View FOXA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | Lentivirus-mediated HTML-verified full-length expression for robust cell-based functional assays. |
| Transcription Factor Complex Validation | High-purity recombinant proteins with native-like folding verified by theoretical MW. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included. |
| Off-Target Effects | Validated siRNA sets included for target-specific knockdown control. |
Live HOXC13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HOXC13 is an emerging frontier in oncology. As an intracellular homeobox transcription factor, HOXC13 is historically considered "undruggable" via traditional monoclonal antibodies. However, the race for HOXC13 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) inhibitors, antisense oligonucleotides (ASOs), and RNA interference (RNAi) modalities. As first-generation discovery programs reach the clinic, the next wave of R&D is targeting the disruption of the HOXC13-AR/FOXA1 transcriptional complex in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI | Biotech Startups, Academic Consortia | Castration-Resistant Prostate Cancer (CRPC) | In vitro binding assays (Need high-purity recombinant HOXC13 protein) |
| RNAi / ASO | Oligonucleotide Therapeutics Developers | Metastatic Breast Cancer, Lung Adenocarcinoma | Target knockdown validation (Need verified HOXC13 siRNA & Lentivirus) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Pioneers | Esophageal Squamous Cell Carcinoma (ESCC) | Degradation kinetics assays (Need stable overexpressing cell lines via Lentivirus) |